Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
Primary Purpose
Obesity, Overweight, Fatty Liver
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Almond
Cereal Bar
Sponsored by
About this trial
This is an interventional treatment trial for Obesity focused on measuring Obesity, Overweight, Body Weight, Cardiovascular Diseases, Cholesterol, Almonds, Visceral Adiposity, Quality of Life, Hispanic Americans, African Continental Ancestry Group, Metabolic Syndrome X
Eligibility Criteria
Inclusion Criteria:
- Black and/or Hispanic
- Body Mass Index (BMI) 25-35 kg/m^2
- Weight stable (+/- 2.5 kg) for at least 3 months prior to screening
- Body weight less than 300 pounds
- Adherence to an acceptable form of contraception (for women)
- If taking medicine, dose must have been stable before study; must remain on same medication and dose throughout study.
Exclusion Criteria:
- Diabetes
- Uncontrolled hypertension (high blood pressure)
- Cardiovascular disease
- Weight loss attempted in past 3 months
- Eating disorder
- Stroke, seizure disorder, or significant neurological disease
- Unstable of uncontrolled medical illness including active malignancies within past 5 years
- Untreated or unstable hypothyroidism
- Hyperthyroidism
- Diagnosis of psychoses, bipolar disorder, major depression, severe personality disorder; history of suicidal tendencies
- Alcohol or substance abuse in the past 6 months
- Pregnant, planning pregnancy in the next 6 months, or breast-feeding
- Participating or planning to participate in a commercial diet or behavior modification program (ex: Weight Watchers)
- Allergy or sensitivity to wheat/grain products or nuts
- Gastrointestinal disorder.
Sites / Locations
- New York Nutrition Obesity Research Center
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
Almond
Cereal Bar
Arm Description
Outcomes
Primary Outcome Measures
Change in body Composition
MRI will be used to provide information on total adipose tissue and all adipose tissue sub-compartments: visceral, subcutaneous, intermuscular.
Change in liver Fat
MRS will be used to provide information on liver adiposity.
Secondary Outcome Measures
Change in cardio-metabolic risk profile
Blood draw and analyses will be used to measure total and low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, glucose, insulin, and inflammatory markers.
Change in brain-derived neutrophic factor (BDNF)
Blood draw and analyses will be used measure BDNF.
Change in quality of life
SF-36 questionnaire will be used to assess quality of life.
Full Information
NCT ID
NCT02347007
First Posted
January 16, 2015
Last Updated
January 9, 2020
Sponsor
Columbia University
Collaborators
Almond Board of California
1. Study Identification
Unique Protocol Identification Number
NCT02347007
Brief Title
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
Official Title
Impact of Almond Supplementation, Relative to a Low-fat, High Carbohydrate Control, on Body Composition in Overweight and Obese Black and Hispanic Adults
Study Type
Interventional
2. Study Status
Record Verification Date
January 2020
Overall Recruitment Status
Completed
Study Start Date
October 2014 (Actual)
Primary Completion Date
June 2016 (Actual)
Study Completion Date
March 2019 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Columbia University
Collaborators
Almond Board of California
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to determine whether introducing almonds into the diet of overweight and obese Blacks and Hispanics improves body composition, decreases liver fat, and lowers cardiovascular disease profile.
Detailed Description
The study is a randomized, controlled study aimed at testing whether almonds, consumed within a free-living, self-selected diet, improve body composition and liver fat, relative to a low-fat/high-carbohydrate cereal bar (LF-HC) in overweight and obese Blacks and Hispanics. A secondary aim is to determine whether almond consumption will lead to an overall lower CVD risk profile.
Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily (2-3 oz) or a high-carbohydrate cereal bar (2 g of fat or less per 100 kcal) providing an equivalent amount of calories. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their food supplement as a mid-afternoon snack and the rest at a meal of their choice.
At the baseline visit, participants will be given a 2-week supply of their allocated food supplement and will obtain additional supplies at bi-weekly visits for the first 8 weeks. After the week 8 visit, participants will be given monthly rations of their food supplement, either almonds or LF-HC cereal bar, and will be asked to come to research center every 4 weeks to obtain their next supply. At those visits, body weight and blood pressure will be measured and participants will turn in weekly dietary diaries, reporting their supplement intake. Participants will also receive one random phone call every 4 weeks to provide a 24-h recall. This recall will be used as an index of dietary quality but also as a compliance check with dietary supplements. In addition, 3-day food records will be collected prior to the start of the study and during the final week to assess any dietary changes due to the intervention. A food frequency questionnaire will also be administered at screening and endpoint of the study. This food-frequency questionnaire will target nut consumption.
At the end of the study, intention to continue eating almonds or a low-fat diet will be assessed using questions adapted from de Bruijn et al. Participants in the almond group will be asked the following questions: (1) "I intend to include almonds in my diet" (+2 = yes, definitely; -2 = no, definitely); (2) "How certain are you that you will include almonds in your diet?" (+2 = very certain; -2 = very uncertain); (3) "Including almonds in my diet is" (instrumental attitude: +3 = healthy; -3 = unhealthy; affective attitude: +3 = pleasant; -3 = unpleasant); (4) "I find including almonds in my diet" (perceived behavioral control: +3 = easy; -3 = difficult). Corresponding questions for the control group will replace "include almonds" with "reduce the amount of fat". Participants will be called 4 weeks later to obtain information on their actual almond and fat intakes by questionnaire and 24-h recall.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Overweight, Fatty Liver, Metabolic Syndrome X
Keywords
Obesity, Overweight, Body Weight, Cardiovascular Diseases, Cholesterol, Almonds, Visceral Adiposity, Quality of Life, Hispanic Americans, African Continental Ancestry Group, Metabolic Syndrome X
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
26 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Almond
Arm Type
Experimental
Arm Title
Cereal Bar
Arm Type
Active Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
Almond
Intervention Description
Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
Intervention Type
Dietary Supplement
Intervention Name(s)
Cereal Bar
Intervention Description
Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
Primary Outcome Measure Information:
Title
Change in body Composition
Description
MRI will be used to provide information on total adipose tissue and all adipose tissue sub-compartments: visceral, subcutaneous, intermuscular.
Time Frame
Baseline and endpoint visits (Weeks 0 and 24)
Title
Change in liver Fat
Description
MRS will be used to provide information on liver adiposity.
Time Frame
Baseline and endpoint visits (weeks 0 and 24)
Secondary Outcome Measure Information:
Title
Change in cardio-metabolic risk profile
Description
Blood draw and analyses will be used to measure total and low-density lipoprotein cholesterol, triglycerides, high-density lipoprotein cholesterol, glucose, insulin, and inflammatory markers.
Time Frame
Baseline, midpoint, and endpoint visits (weeks 0, 12, and 24)
Title
Change in brain-derived neutrophic factor (BDNF)
Description
Blood draw and analyses will be used measure BDNF.
Time Frame
Baseline, midpoint, and endpoint visits (weeks 0, 12, and 24)
Title
Change in quality of life
Description
SF-36 questionnaire will be used to assess quality of life.
Time Frame
Baseline and endpoint visits (weeks 0 and 24)
10. Eligibility
Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Black and/or Hispanic
Body Mass Index (BMI) 25-35 kg/m^2
Weight stable (+/- 2.5 kg) for at least 3 months prior to screening
Body weight less than 300 pounds
Adherence to an acceptable form of contraception (for women)
If taking medicine, dose must have been stable before study; must remain on same medication and dose throughout study.
Exclusion Criteria:
Diabetes
Uncontrolled hypertension (high blood pressure)
Cardiovascular disease
Weight loss attempted in past 3 months
Eating disorder
Stroke, seizure disorder, or significant neurological disease
Unstable of uncontrolled medical illness including active malignancies within past 5 years
Untreated or unstable hypothyroidism
Hyperthyroidism
Diagnosis of psychoses, bipolar disorder, major depression, severe personality disorder; history of suicidal tendencies
Alcohol or substance abuse in the past 6 months
Pregnant, planning pregnancy in the next 6 months, or breast-feeding
Participating or planning to participate in a commercial diet or behavior modification program (ex: Weight Watchers)
Allergy or sensitivity to wheat/grain products or nuts
Gastrointestinal disorder.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marie-Pierre St-Onge, Ph.D.
Organizational Affiliation
College of Physicians & Surgeons, Columbia University
Official's Role
Principal Investigator
Facility Information:
Facility Name
New York Nutrition Obesity Research Center
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
12. IPD Sharing Statement
Learn more about this trial
Impact of Almond Supplementation on Body Composition in Overweight/Obese Minority Adults
We'll reach out to this number within 24 hrs